Corporate Banner
Satellite Banner
Technology Networks Header
Friday, April 18, 2014
Technology Networks
 
Register | Sign in
Home Page
  Permissions

Permission to use, copy and distribute documents presented on this World Wide Web site and related graphics is not granted without prior written permission of Technology Networks Ltd

To obtain this permission contact:
Technology Networks Ltd
Unit 6, Woodview
Bull Lane
Acton
Sudbury
CO10 0FD, U.K.

In cases where permission is granted, it is done so under the provision that the above copyright notice and this permission notice appear in all copies. All other rights are reserved.

The information and data included in the TechnologyNetworks.com WWW site, and all its affiliated websites and associated email newsletters, have been compiled from a variety of sources, and are subject to change without notice. Technology Networks Ltd. makes no warranties or representations whatsoever regarding the quality, content, completeness, or adequacy of this information and data.

Technology Networks Ltd. specifically disclaims all warranties with respect to this WWW site, email newsletters or your use thereof, express, implied, or otherwise, including without limitation, all warranties of merchantability and fitness for a particular purpose. Technology Networks Ltd shall not be liable for any special, incidental, or consequential damages, including, without limitation, lost revenues, lost profits, or loss of prospective economic advantage, resulting from the use or misuse of this site, or the information therein.

Scientific News
A Metabolomic Perspective on Coeliac Disease
Metabolomics has proved to be a useful complement for the characterization of several physiological and pathological conditions and offers promises as a clinical tool.
Underlying Genetics and Marker For Stroke Discovered
NIH-funded findings point to new potential strategies for disease prevention, treatment.
BIOCRATES Test Kit Helps Develop First Metabolomics-Based Blood Test for Alzheimer’s
The test is capable of predicting, with 90% accuracy, the risk of Alzheimer’s disease 2–3 years before it has actually become clinically manifest.
The Role of Mass Spectrometry in the "Omics" Era
The tremendous developments of the MS technology and concurrent gene sequencing efforts have made the “-omic” revolution possible.
Metabolomics: Taking Aim at Diabetic Kidney Failure
Krolewski and his Joslin colleagues search for better ways of predicting which diabetic people are at risk for ESRD.
Omega-3 Fatty Acids have Wider Range of Biological Impacts
Study explored the challenges the liver faces from the “Western diet” that increasingly is linked to liver inflammation, fibrosis, cirrhosis and sometimes liver failure.
Speeding Validation of Disease Targets
NIH, industry and non-profits join forces to develop new treatments earlier, beginning with Alzheimer’s, type 2 diabetes, and autoimmune disorders.
Fatty Liver Disease Reversed in Mice
Epilepsy drug also shown to decrease obesity-related blood sugar levels.
GW Receives up to $14.6M to Develop Method for Characterizing Security Threats
The researchers are tasked with reducing to 30 days a process that can sometimes take years or even decades.
Metabolomics Reveals a Role for the Chromatin-Binding Protein HMGN5 in Glutathione Metabolism
This study links the expression of HMGN5 to transcriptional changes that affect glutathione metabolism in the liver.
Skyscraper Banner
Skyscraper Banner
Follow TechNetcom1 on Twitter
Technology Networks Ltd. on LinkedIn
Go to LabTube.tv